(ALTR:Consolidated Issue Listed on NASDAQ Global Select )
Susan S. Wang
Former Director and Chairman of Audit Committee, Altera Corp.
|Age||Total Calculated Compensation||This person is connected to 56 board members in 4 different organizations across 10 different industries.|
See Board Relationships
Ms. Susan S. Wang served as the Chief Financial Officer, Executive Vice President of Corporate Development and Corporate Secretary at Solectron Corporation. Ms. Wang retired from Solectron in June 2002 and has held several key positions during her 18 years. She is a Financial Expert. Before joining Solectron in 1984, Ms. Wang held financial and managerial positions with Xerox Corporation , Westvaco Corporation, Price Waterhouse LLP and Price Waterhouse & Co. She has ...
101 Innovation DrivePhone: 408-544-7000
San Jose, California 95134
Board Members Memberships*
Former Director, Chairman of Audit Committee and Member of Compensation Committee
Former Director and Chairman of Audit Committee
Independent Director and Chairman of Audit Committee
Former Independent Director, Chairman of Audit Committee and Member of Executive Committee
Former Independent Director and Chairman of Audit Committee
Former Chairwoman and Member of Audit Committee
Director and Chairman of Audit Committee
Independent Director, Chairman of Audit & Compliance Committee and Member of Member Agreement Review Committee
The University of Texas System
University of Connecticut
Annual Compensation*There is no Annual Compensation data available.
Stock Options*There is no Stock Options data available.
|Michael W. Aguiar||Chief Executive Officer, President and Director|
|Peter M. Hecht Ph.D.||Co-Founder, Chief Executive Officer and Director|
Ironwood Pharmaceuticals, Inc.
|James A. Schoeneck||Chief Executive Officer, President and Director|
|Peter S. Greenleaf||Chief Executive Officer and Director|
Sucampo Pharmaceuticals, Inc.
|Daniel J. Abdun-Nabi||Chief Executive Officer, President, Director, Member of Strategic Operations Committee and Member of Pricing Committee|
Emergent BioSolutions, Inc.
|$1.2M||Compensation as of Fiscal Year 2014.|